Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Mirati Therapeutics Inc.
MGCD265 belongs to a new class of drugs with anticancer potential, known as tyrosine kinase inhibitors. MGCD265 was shown to slow down the growth of human cancer cells in mice. Clinical studies are being pursued to evaluate the safety of MGCD265 in cancer patients. In this study, MGCD265 is orally administered on a daily basis to patients with advanced malignancies.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
